The AGNIFS survey: spatially resolved observations of hot molecular and ionised outflows in nearby active galaxies

We present the hot molecular and warm ionised gas kinematics for 33 nearby ($0.001\lesssim z\lesssim0.056$) X-ray selected active galaxies using the H$_2 2.1218 \mu$m and Br$\gamma$ emission lines observed in the K-band with the Gemini Near-Infrared Field Spectrograph (NIFS). The observations cover the inner 0.04$-$2 kpc of each AGN at spatial resolutions of 4$-$250 pc with a velocity resolution of $\sigma_{\rm inst}\approx$20 ${\rm km s^{-1}}$. We find that 31 objects (94 per cent) present a kinematically disturbed region (KDR) seen in ionised gas, while such regions are observed in hot molecular gas for 25 galaxies (76 per cent). We interpret the KDR as being due to outflows with masses of 10$^2-$10$^7$ M$_\odot$ and 10$^0-$10$^4$ M$_\odot$ for the ionised and hot molecular gas, respectively. The ranges of mass-outflow rates ($\dot{M}_{\rm out}$) and kinetic power ($\dot{E}_{\rm K}$) of the outflows are 10$^{-3}-$10$^{1}$ M$_\odot$yr$^{-1}$ and $\sim$10$^{37}$$-$10$^{43}$ erg s$^{-1}$ for the ionised gas outflows, and 10$^{-5}$$-$10$^{-2}$ M$_\odot$ yr$^{-1}$ and 10$^{35}$$-$10$^{39}$ erg s$^{-1}$ for the hot molecular gas outflows. The median coupling efficiency in our sample is $\dot{E}_{K}/L_{\rm bol}\approx1.8\times10^{-3}$ and the estimated momentum fluxes of the outflows suggest they are produced by radiation-pressure in low-density environment, with possible contribution from shocks.Comment: 37 pages, published in MNRAS - A few typos in the text and in the label of Fg 1 were corrected in this versio

A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals

Glucosamine (GlcN) is a widely utilized dietary supplement that is used to promote joint health. Reports that oral GlcN supplementation at usual doses adversely affects glucose metabolism in subjects with impaired glucose tolerance have raised concerns that GlcN should be contraindicated in individuals with diabetes and those at risk for developing it. This review addresses its potential, when used at typical doses, to affect glucose metabolism and insulin sensitivity in healthy individuals and those with diabetes or ‘pre-diabetes’. Publicly available scientific information and data on GlcN were systematically compiled using the electronic search tool, Dialog®, and reviewed with special emphasis on human studies. In long-term clinical trials, including those containing subjects with type 2 diabetes or ‘pre-diabetes’, GlcN produced a non-significant lowering of fasting blood glucose concentrations in all groups of subjects treated for periods of up to 3 years. Owing to limitations in study design, conclusions based on studies that report adverse affects of GlcN on insulin sensitivity and glucose tolerance in pre-diabetic subjects are suspect. However, no definitive long-term studies of GlcN use for individuals with pre-diabetes are available. Nevertheless, based on available evidence, we conclude that GlcN has no effect on fasting blood glucose levels, glucose metabolism, or insulin sensitivity at any oral dose level in healthy subjects, individuals with diabetes, or those with impaired glucose tolerance